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Background: Alpha-fetoprotein (AFP)-producing rectal cancer is very rare, and this type of cancer frequently
metastasizes to the liver with a poor prognosis. To date, only 11 cases of AFP-producing colorectal cancer have
been reported.
Case presentation: A 41-year-old woman was first presented to the hospital for anal bleeding. An elevated tumor with
a central shallow depression in the lower rectum was detected by colonoscopy. Transanal excision was performed, and
the histology revealed adenocarcinoma. Further immunohistopathological examination revealed that the tumor was an
AFP-producing adenocarcinoma of the rectum. Although local resection was performed 2 months before the diagnosis
of AFP tumor, the serum AFP level was normal. The depth of the submucosal invasion was 5,000 μm, and there was
venous invasion. Also, no lymphatic invasion was detected. Therefore, additional surgical resection with lymph node
dissection was conducted, and the patient underwent laparoscopic intersphincteric resection. No residual cancer was
identified in the surgical specimens, and there was no evidence of lymph node metastasis. The patient was discharged
18 days postoperatively, and 12 months after the operation, there are no signs of recurrence.
Conclusion: To the best of our knowledge, this is the first case of an AFP-producing rectal cancer that was diagnosed at
an early stage.
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Alpha-fetoprotein (AFP), a serum glycoprotein with a
molecular weight of approximately 70 kDa, develops
during gestation and is produced from fetal liver and
yolk sac [1]. It was first described in 1963 by Abeleb et
al. [2]. Immediately after birth, serum AFP levels are
high, approximately 10,000 ng/mL but decrease rapidly,
and by the second year of life and thereafter are less
than 10 ng/mL. Some tumors produce AFP and lead to
an increase in serum AFP levels. Therefore, AFP is a
useful tumor marker in the diagnosis of tumors, such as
hepatocellular carcinomas, hepatoblastoma, and yolk sac
tumors [3-5]. AFP-producing tumors have mainly been re-
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unless otherwise stated.[6]. The majority of AFP-producing cancers originate from
the stomach, bile duct, and pancreas. However, AFP-
producing colorectal cancer is extremely rare because the
colorectum originates from the hindgut endoderm. Only 11
cases of AFP-producing colorectal cancer have been re-
ported in English literature to date. Here, we report a case
with early rectal cancer diagnosed as an AFP-producing
tumor by immunohistochemistry. AFP-producing tumors
have been reported to frequently metastasize to the liver
and have a poor prognosis. However, the tumor in the
present case was diagnosed at an early stage and no distant
metastases were detected simultaneously [7-17]. To the
best of our knowledge, this is the first case of an early
diagnosis of an AFP-producing rectal cancer reported in
English literature.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 41-year-old woman first noticed anal bleeding in
December 2013. She had initially presented to a local
hospital, and a colonoscopy was performed. Colonos-
copy revealed an elevated tumor of approximately 15
mm in diameter with a central shallow depression in the
lower rectum. It appeared similar to mucosal prolapse
syndrome, and the histopathology of the biopsy specimen
revealed no malignancy (Figure 1). Transanal excision of
the elevated tumor was performed. The histopathological
diagnosis of the tumor revealed a moderately differentiated
adenocarcinoma. The patient was referred to our hospital
for further investigation. Laboratory data investigations re-
vealed normal serum hemoglobin. Tumor markers, such as
carcinoembryonic antigen, carbohydrate antigen 19-9, and
serum anti-p53 antibody, were within the normal ranges at
1.2 ng/ml (normal range 0 to 5.0 ng/ml), 11 U/ml (normal
range 0 to 37.0 U/ml), and 0.40 U/ml (normal range 0 to
0.40 U/ml), respectively. Although elevated AFP levels take
several months to normalize after the resection, the serum
levels of 2 months after resection were within normal limits
at 2 ng/ml (normal range 0 to 10.0 ng/ml). Abdominal
computed tomography did not reveal liver metastasis,
enlarged lymph nodes, or peritoneal metastasis, and the
resected tumor was re-examined at our hospital. The
schematic drawing of intraoperative situation is shown in
Figure 2. Microscopically, the tumor comprised columnar
neoplastic cells with clear cytoplasm showing tubular
structure and focal solid growth by examination of the
hematoxylin-eosin staining (Figure 3A). Most of the tumor
was clear cell carcinoma, and the conventional adenocar-
cinoma present very focally (Figure 4). Immunohistochem-
istry using an anti-AFP antibody demonstrated diffused and
strong positive staining of the cytoplasm of the neoplastic
cells (Figure 3B). These results led to the diagnosis of AFP-
producing adenocarcinoma of the rectum. The depth of the
submucosal invasion was 5,000 μm, and there was a posi-
tive venous invasion (Figure 3C). Both these findings were
suggestive of possible lymph node metastasis; therefore, weA
Figure 1 Colonoscopy findings. (A) Macroscopic evaluation by colonoscop
depressed area can be seen at its center. (B) The surface of the elevated tuadvocated additional surgical resection with lymph node
dissection. Furthermore, the patient underwent laparo-
scopic intersphincteric resection in March 2014. The histo-
pathological report revealed no residual tumor in the
surgical specimens and no lymph node metastasis. The pa-
tient was discharged 18 days postoperatively, and 12
months later, there are no signs of recurrence.
Conclusions
We report on a patient with AFP-producing rectal can-
cer diagnosed at an early stage. Although local resection
was performed 2 months before the diagnosis of AFP
tumor, the serum AFP levels of 2 months after the initial
operation were normal. In Japanese literature, there are
only two reported cases of AFP-producing colorectal
disease detected in the early stages, which were T1 N0
and T2 N0 colorectal cancer, respectively[18,19]. AFP-
producing cancer is defined by positively stained tumor
of anti-AFP monoclonal antibody. Several reports de-
scribe that AFP-producing gastric cancer (AFP-GC) has
an aggressive clinical course and poorer prognosis than
AFP-negative GC. Interestingly, there are similarities
with AFP-producing colorectal cancer and AFP-GC that
it rapidly progresses and frequently metastasizes into the
liver and show poor prognosis.
In present case, immunohistochemically evaluated
glypican-3 expression, which is reported to be a sensi-
tive marker for AFP-GC, was positive [20]. The immu-
nohistochemical feature of present case was similar to
AFP-GC. However, the histological characterization of
AFP-producing colorectal cancer differs from AFP-
GC. Although the most common subtype of AFP-GC
is poorly differentiated carcinoma, poorly to moder-
ately differentiated carcinoma is commonly observed
among AFP-producing colorectal cancer. Additionally
AFP-producing colon cancer is extremely rare, with
only 11 reported cases in English literature [7-17]. The
clinicopathological findings of these cases are summa-
rized in Table 1. Of these 11 cases, 10 had elevatedB
y showed an elevated tumorous lesion in the lower rectum. A shallow
mor showed redness.
A B
Figure 2 Schematic drawing of intraoperative situation. (A) Schematic drawing of intraoperative situation. (B) A schematic drawing of resected specimen.
A B
C
Figure 3 Microscopic findings. (A) Microscopic evaluation with hematoxylin-eosin staining of the tumor reveals columnar neoplastic cells with
clear cytoplasm (original magnification, ×20). (B) Immunohistochemical staining of the tumor using an antibody against AFP. Diffused and strong
positive staining is observed in the cytoplasm of the neoplastic cells (original magnification, ×20). (C) Elastic Van Gieson staining of the tumor
reveals venous invasion by the adenocarcinoma (original magnification, ×25).
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Figure 4 Histological mapping of cut surface ③.
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mon tumor site and almost all cases had extensive
simultaneous liver metastasis. Of the 11 cases, 6 cases
died of the primary AFP-producing tumor and 2 cases
died of postoperative complications. In addition, al-
though almost all reports demonstrate the poor prog-
nosis of AFP-producing tumors, there was no distant
metastasis or recurrence in the present case. Although
there are several reports of an AFP-GC with features
of hepatic differentiation, the mechanisms of AFP-
producing rectal cancer or the hepatic differentiation
remain obscure.
Several studies have demonstrated the histopatho-
logical factors that predict lymph node metastasis of
T1 stage colorectal cancer. The rate of lymph node
metastasis of submucosal cancer has been reported to
be 6% to 12% [21]. The risk factors for lymph node







1 Nakajima et al. [7] 50/M R 3,018 NS
2 Yu et al. [8] 54/M R 5,126 Ulcerated
3 Sato et al. [9] 43/M R 7,060 Ulcerated
4 Hocking et al. [10] 39/F S/C 7,200 NS
5 Kato et al. [11] 75/M C 3,070 Ulcerated
6 Taguchi et al. [12] 71/M R 220,000 Ulcerated
7 Kurihara et al. [13] 67/M T/C 10,978 Ulcerated
8 Ishikura et al. [14] 48/F S/C 6,600 Ulcerated
9 Lattes et al. [15] 41/M R NS Ulcerated
10 Yachida et al. [16] 59/M T/C 12,873 Ulcerated
11 Fu et al. [17] 71/M T/C 318 Ulcerated
12 Present case 41/F R 2 Elevated
AFP = alpha-fetoprotein; NS = not stated; C = cecum; S/C = sigmoid colon; T/C = tr
mod = moderately differentiated adenocarcinoma; por = poorly differentiated aden
aAdenocarcinoma showing hepatoid morphology; bglandular differentiation consistpoor differentiation, lymphatic invasion, vascular inva-
sion, deep submucosal invasion, or a positive resection
margin [22-24]. In the present case, the risk factors of
massive invasion and vascular invasion were detected,
which led us to perform the additional surgery.
In conclusion, we report on an AFP-producing colon
cancer diagnosed at an early stage, whereby early de-
tection enabled a complete resection of the carcinoma.
It is important to note that management of a patient
with an elevated tumor with a shallow depression, even
when no malignancy is detected, should include local
excision for immunohistopathological analysis. Al-
though serum AFP levels have been high in all previ-
ously reported cases, it is important to remember that
serum AFP levels may not rise in the early stages of
AFP-producing cancer. Further accumulation of data











Prostate + Liver/lung Mod-por 5M dead
Serosal + Liver Well 0M dead
Extraserosal + Liver Well-mod 4M dead
Perforation + Liver a 1M dead
NS + No Por 4M dead
Muscular - No b 12M dead
Serosal + Liver Por NS
Subserosal NS Liver Well 4M dead
NS + Liver Well-muc-sig 12M alive
Serosal - Liver Well 2M dead
Subserosal - No Por 5Y alive
Submucosal - No Mod-por 2M alive
ansverse colon; R = rectum; well = well differentiated adenocarcinoma;
ocarcinoma; muc = mucinous adenocarcinoma; sig = signet-cell-carcinoma;
ed of columnar cancerous cells.
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